AbbVie Reports Phase 3 Skyrizi Endoscopic Outcomes in Crohn's Disease
AbbVie reported new Phase 3 AFFIRM data on endoscopic outcomes with subcutaneous Skyrizi in adults with moderately to severely active Crohn's disease.
Related stories
Nemesia’s Faraday Copper Stake Falls to About 13.25% After Dilution
Nemesia bought 971,830 Faraday Copper shares at Cdn$4.4622, but its holding fell from about 19.11% to about 13.25% after the company issued shares for its San Manuel deal. Nemesia
M impact | EQUITY | Oct 31, 2026, 12:00 AM UTC
São Paulo Stock Market Falls for the Week After Lula Election Victory
São Paulo’s stock market fell for the week following Lula’s election victory.
M impact | EQUITY | Oct 30, 2026, 11:34 PM UTC
Intel shares plunge, their worst day since 1974
H impact | EQUITY | Oct 30, 2026, 11:34 PM UTC
Buenos Aires Stock Market Closes Lower
The Buenos Aires stock market closed lower.
M impact | EQUITY | Oct 30, 2026, 11:34 PM UTC
S&P Global Revises Meta Outlook to Negative on AI Spending Concerns
S&P Global revised its outlook on Meta Platforms to negative, citing AI spending and cash-flow concerns.
M impact | EQUITY | Oct 30, 2026, 11:28 PM UTC
Mexican Stock Market Ends Steady, Gains More Than 8% for Month
Mexico’s stock market closed steady, with a monthly gain of more than 8%.
M impact | EQUITY | Oct 30, 2026, 11:24 PM UTC